About
Hamid Khoja, Ph.D., is Chief Scientific Officer of FibroBiologics, a Houston-based clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases and regenerative medicine applications. He joined FibroBiologics in August 2021 and previously held scientific roles at Covaris, Genomic Solutions, Sequenom, Eli Lilly, and Chiron. His background is centered on molecular biology, genomics, proteomics, epigenetics, and cell-therapy R&D.
Areas of interest
biotechcell therapyregenerative medicinefibroblast therapeuticswound healingmultiple sclerosispsoriasisdisc degenerationgenomicsproteomicsepigeneticsclinical diagnosticslongevity